Journal de recherche et de traitement en oncologie

Abstrait

Is Endocan a Novel Prognostic Marker for Colorectal Cancer?

Korkmaz UB , Akyol M , Alacacioglu A , Salman T *, Varol U , Küçükzeybek Y , Oflazoglu U and Uzum Y

Purpose: The present study aimed to investigate the relationship between pretreatment serum Endocan levels and pretreatment serum VEGF levels in colorectal cancer cases, as well as colorectal cancer prognosis. Methods: This study included a control group of 16 individuals and a patient group of 67 cases with colorectal cancer. Serum VEGF and Endocan levels were determined with enzyme-linked immunosorbent assay (ELISA) kits used for scientific research purposes. Results: The examinations showed no significant relations between serum endocan level and prognosis. Also, no significant difference was detected between the patient group and control group in terms of height, weight, age or BMI levels. The examinations indicated no significant difference between the groups except for the VEGF level. VEGF levels in metastatic colorectal cancer cases were significantly higher than the control group and the tumor-free colorectal cancer cases (p: 0.005, p: 0.038; respectively). Conclusion: This study showed that there was no significant relationship between pretreatment Endocan levels and VEGF levels, as well as prognosis.